DOT Drug Testing Is Changing: What Washington Carriers Need to Know About Fentanyl and the June 2026 Rule Update

Two separate federal regulatory actions are affecting DOT drug and alcohol testing programs this year. One involves a proposed expansion of the standard testing panel to include fentanyl. The other is a final rule that took effect June 10, 2026. Washington motor carriers need to understand both, because one requires action now and the other requires preparation.

The Fentanyl Proposed Rule: Where It Stands Today

On September 2, 2025, the U.S. Department of Transportation published a Notice of Proposed Rulemaking in the Federal Register proposing to add fentanyl and its primary metabolite norfentanyl to the standard DOT drug testing panel under 49 CFR Part 40. The public comment period closed October 17, 2025.

As of June 2026, a final rule has not yet been published and no confirmed effective date exists. This is an important distinction. Fentanyl is not yet on the DOT testing panel for FMCSA-regulated CDL drivers. Carriers do not need to take immediate action on testing panel changes, but they do need to be preparing.

Here is why this rule matters and why it is coming regardless of the final timeline. The Department of Health and Human Services updated its Mandatory Guidelines to add fentanyl and norfentanyl effective July 7, 2025. Those guidelines govern federal employee testing. The DOT program, which covers private-sector transportation workers including CDL drivers, operates under a separate regulation and must be updated independently. The HHS change is the precursor. The DOT rule follows. The only open question is when.

Fentanyl is 50 to 100 times more potent than morphine and drives more than 70 percent of opioid overdose deaths in the United States. It increasingly appears in substances that users do not know contain it. For safety-sensitive workers operating commercial motor vehicles, the risk profile is severe enough that this rule was always going to move forward.

What the Fentanyl Rule Will Change When Finalized

Under the proposed rule, the current DOT 5-panel urine test would expand to include fentanyl and norfentanyl. The existing five categories are marijuana, cocaine, opiates, amphetamines, and phencyclidine. Fentanyl is a synthetic opioid that is chemically distinct from the opiates currently on the panel, which is why it requires a separate addition. A driver who uses fentanyl today would not necessarily trigger a positive on the current DOT test.

The proposed rule also updates Medical Review Officer verification procedures to address fentanyl results. This matters because fentanyl has legitimate medical uses and is prescribed for pain management. The MRO verification process ensures that a driver with a lawful prescription is not incorrectly disqualified.

If your written drug and alcohol testing policy currently references a "DOT 5-panel test" by name, that language will need to be updated once the final rule is published. This is a routine policy update, not a program overhaul. Your C/TPA and MRO will handle the testing panel changes on the backend. What you own as an employer is your written policy.

The June 10, 2026 Final Rule: This One Is Already in Effect

While the fentanyl rule remains pending, a separate DOT final rule took effect on June 10, 2026. This rule makes two changes to 49 CFR Part 40.

The first change updates terminology throughout the DOT drug and alcohol testing regulations in alignment with Executive Order 14168. This is primarily a language update and does not alter testing procedures or requirements in a substantive way for most carriers.

The second change is more operationally significant. The rule adds a new provision requiring a directly observed urine collection in situations where oral fluid testing would otherwise be required but oral fluid testing is not yet available. This addresses a gap created by the fact that DOT authorized oral fluid testing as an alternative collection method, but as of January 2026 no HHS-certified laboratories exist to process DOT oral fluid specimens. The rule creates a fallback: if a testing situation calls for oral fluid and oral fluid is not available, the collection must proceed as a directly observed urine collection instead.

For most Washington carriers currently running urine-based DOT testing programs, this change has no immediate impact on day-to-day operations. However, if your program or your C/TPA has been discussing oral fluid testing as an option, this rule clarifies exactly what happens in the interim period before certified labs come online.

What Washington Carriers Should Do Right Now

On the fentanyl rule, there are three practical steps that make sense before the final rule is published.

Review your written drug and alcohol testing policy. If it references the DOT 5-panel by name, flag that language for update. Your C/TPA should notify you when the final rule is published and provide guidance on policy revisions. If you need a policy review, our DOT Compliance program includes written policy management.

Make sure your DER knows this change is coming. The Designated Employer Representative is the person inside your company who receives test results and manages the program. A positive fentanyl result processed through an updated panel will go through the same MRO verification process as any other positive. The DER's role does not change, but awareness matters. If your DER needs formal training, Skyside offers DER Training for FMCSA-regulated employers.

Do not attempt to add fentanyl testing to your DOT program before the final rule is in effect. The DOT testing panel is fixed by federal regulation. Adding substances to your DOT test before they are officially on the panel creates a compliance problem, not a solution. If you want to screen for fentanyl before the rule takes effect, a separate non-DOT test is the correct approach. It must be collected separately, documented separately, and cannot substitute for the DOT test. Our Non-DOT Programs page covers how expanded employer testing works outside the federal panel.

On the June 10 rule, review your current collection protocols with your C/TPA to confirm that directly observed collection procedures are documented and understood for situations where they apply.

The Bigger Picture for Your Testing Program

Both of these regulatory developments point in the same direction. DOT drug testing requirements are expanding in scope, and the administrative burden on motor carriers is increasing. The carriers who navigate this without disruption are the ones who have a properly structured program with a C/TPA managing the compliance details, not the ones trying to track Federal Register updates on their own.

A compliant DOT drug and alcohol testing program for a Washington motor carrier is not a one-time setup. It is an ongoing managed program that requires updates when regulations change, policy revisions when rules are finalized, and a C/TPA relationship that keeps you current without requiring you to monitor federal rulemaking yourself.

Next Steps

Skyside Compliance LLC is a licensed Consortium and Third-Party Administrator operating in Washington State. We manage DOT drug and alcohol testing programs for motor carriers and will update client programs automatically when the fentanyl final rule takes effect. If you are not certain your current program is structured correctly or your written policy is current, a compliance review is the right starting point.

Contact us at (425) 476-7197 or info@skysidecompliance.com to schedule a review. There is no charge for the initial conversation.